Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell's Gene Editing Platform and Oncology Product Portfolio

Transaction adds comprehensive gene editing capabilities and engine to drive expansion of Abcam's 'off-the-shelf' edited cell line portfolio